Trogenix
Trogenix develops precision genetic medicines using its Odysseus platform, which harnesses Synthetic Super-Enhancers (SSEs) to distinguish cancer cell states from healthy ones and drive selective payload delivery. Its methodology combines controlled cell killing, immune modulation, and long-term protection against recurrence. The company pursues therapeutic programmes in aggressive solid tumours, notably glioblastoma, and explores expansion into colorectal liver metastases, hepatocellular carcinoma, and lung cancer. Trogenix also partners with manufacturing and development specialists (e.g. Viralgen) to accelerate production of its gene therapy assets.
Domain
trogenix.com
Country
United KingdomIndustry
BiotechnologyEmployees
1-10
Last Funding
$94.4M
Founded
2022
Tech Stack (18 technologies)
Frequently Asked Questions
What technologies does Trogenix use?+
Trogenix uses 18 technologies including Slider Revolution, WordPress, ExactMetrics.
What industry is Trogenix in?+
Trogenix operates in the Biotechnology industry.
Where is Trogenix based?+
Trogenix is headquartered in United Kingdom.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026